ホーム 計算ツール
代理店ログイン

RANKL/RANK

Receptor activator of nuclear factor kappa-Β ligand (RANKL) is a protein that in humans is encoded by the TNFSF11 gene. Receptor activator of nuclear factor κ B (RANK) is the receptor for RANKL. RANKL/RANK is associated with bone remodeling and repair, immune cell function, lymph node development, thermal regulation, and mammary gland development. Osteoprotegerin (OPG) is a decoy receptor for RANKL, and regulates the stimulation of the RANK signaling pathway by competing for RANKL. The cytoplasmic domain of RANK binds TRAFs 1, 2, 3, 5, and 6 which transmit signals to downstream targets such as NF-κB and JNK.
Cat. No. 製品名 CAS No. Purity Chemical Structure
T9917 Denosumab 615258-40-7 98%
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
T5720 Boldine 476-70-0 98%
Boldine (1,10-Dimethoxy-2,9-dihydroxyaporphine) is a natual product .Boldine displays anti-cancer, cytoprotective , anti-oxidant and anti-inflammatory activities...
T61531 NFATc1-IN-1 1912422-56-0 99.64%
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-os...
T5770 Alisol B 18649-93-9 99.77%
Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol...
T80618 Narlumosbart 2646587-68-8 98%
Narlumosbart (JMT103) is an IgG4κ monoclonal antibody that selectively binds to the receptor activator of nuclear factor-κB ligand (RANKL)[1].
Denosumab
T9917
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
Boldine
T5720
Boldine (1,10-Dimethoxy-2,9-dihydroxyaporphine) is a natual product .Boldine displays anti-cancer, cytoprotective , anti-oxidant and anti-inflammatory activities...
NFATc1-IN-1
T61531
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-os...
Alisol B
T5770
Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol...
Narlumosbart
T80618
Narlumosbart (JMT103) is an IgG4κ monoclonal antibody that selectively binds to the receptor activator of nuclear factor-κB ligand (RANKL)[1].